



IBD **ON AIR** *practice* 2022

**JUNE 20th | 27th
JULY 4th | 11th, 2022**

h. 6:00 - 8:00 PM CEST

COURSE DIRECTORS

**Silvio Danese, *Italy*
Laurent Peyrin-Biroulet, *France***

Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) are chronic diseases that significantly impact on patients' lives.

Novel diagnostic and interventional techniques, imaging modalities and the introduction of biologics and small molecule have dramatically improved their management and outcomes. The main aim of this congress is to focus the attention of practicing IBD experts on the most novel imaging modalities, the use of new drugs, and how to integrate them in daily clinical practice. Several interactive clinical cases will be presented and discussed to deliver the learning objectives.

- Interventional endoscopy in CD management
- Abscess and fistula management outside of perianal region in CD
- Difficult cases in UC
- Small bowel imaging and management
- Pouchitis management
- Clinical challenges in TDM daily practice



ORGANIZATION OFFICE
Materia Prima srl
segreteria@materia1a.it
www.materia1a.it

JUNE 20th, 2022

Welcome and Introduction 5'

DYSPLASIA MANAGEMENT IN ULCERATIVE COLITIS

CLINICAL CHALLENGES IN UC: Histopathology as a driver of clinical choice

Take home message 5'

Satellite Symposium 30'

Targeting the future: The role of histo- endoscopic remission in pts with UC

Chairman | Iris Dotan, Fernando Magro

Silvio Danese, Laurent Peyrin-Biroulet

Marietta Iacucci, Tommaso Parigi

Iris Dotan, Fernando Magro

JUNE 27th, 2022

Welcome and Introduction 5'

SURGICAL CROHN'S DISEASE

COMBINATION STRATEGIES FOR DIFFICULT CASES

Satellite Symposium 30'

Strong start for a better future: Early choices in Crohn's disease management

Chairman | Marc Ferrante, Ryan Ungaro

Silvio Danese, Laurent Peyrin-Biroulet

Willem Bemelman, Vittoria Bellato

Marc Ferrante, Ryan Ungaro

JULY 4th, 2022

Welcome and Introduction 5'

TRANSMURAL VERSUS ENDOSCOPIC HEALING?

ULTRASOUND AS DRIVER OF CLINICAL CHOICE IN IBD

Satellite Symposium 30'

Rerouting Infliximab therapy from IV to SC: Can it Open New Doors?

Chairman | Julian Panés, Mariangela Allocca

Silvio Danese, Laurent Peyrin-Biroulet

Julian Panés, Peter Bossuyt

Mariangela Allocca, Christian Maaser

JULY 11th, 2022

Welcome and Introduction 5'

DIFFICULT TO TREAT IBD

DIFFICULT CASES

Satellite Symposium 30'

The sense of urgency is rising in ulcerative Colitis

Chairman | Subrata Ghosh, Ferdinando D'Amico

Silvio Danese, Laurent Peyrin-Biroulet

Subrata Ghosh, Tim Raine

Ferdinando D'Amico, Britta Siegmund

**REGISTER
HERE**

with the unconditional support of

Janssen Immunology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

abbvie

HEALTHCARE
CELLTRION

Lilly

Takeda

ZERIA GROUP
TILLOTTS PHARMA
GI-health is our passion™